Effective Withdrawal Time and Adenoma Detection Rate
Launched by THE UNIVERSITY OF HONG KONG · Sep 30, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how effectively an artificial intelligence (AI) system can help improve the time spent looking for polyps during colonoscopies, which are procedures used to examine the colon. The goal is to see if there is a connection between the time spent withdrawing the scope and how well doctors can find adenomas, which are small growths that can develop into cancer. The AI will analyze the colonoscopy videos without the doctors knowing the results, to ensure unbiased observations.
To participate in this study, you need to be an adult aged 40 or older and scheduled for an outpatient colonoscopy. However, if you have certain health conditions like inflammatory bowel disease, a history of colorectal cancer, or if you've had parts of your bowel surgically removed, you won't be eligible. Participants can expect to undergo their routine colonoscopy, and the overall goal is to improve the detection of potentially harmful growths in the colon, enhancing the quality of care for patients.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: All adult patients, aged 40 or above, undergoing outpatient colonoscopy will be recruited
- Exclusion Criteria:
- • history of inflammatory bowel disease
- • history of colorectal cancer
- • previous bowel resection (apart from appendectomy)
- • Peutz-Jeghers syndrome, familial adenomatous polyposis or other polyposis syndromes
- • bleeding tendency or severe comorbid illnesses for which polypectomy is considered unsafe.
- • Cecum could not be intubated for various reasons
- • Poor bowel preparation with Boston Bowel Preparation Scale (BBPS) \< 6
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Ka Luen Thomas Lui
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported